Crossmark

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Crossref DOI link: https://doi.org/10.1186/s12885-022-10391-z

Published Online: 2022-12-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shang, Kai

Huang, Hongxiang

Xu, Yongkang

Liu, Yangyang

Lu, Zhihui

Chen, Li
Funding

Funding for this research was provided by:

Medical Scientific Research Foundation from Health Commission of Jiangxi Province (202210473)
License Information

Text and Data Mining valid from 2022-12-12

Version of Record valid from 2022-12-12
More Information

Article History

Received: 24 February 2022

Accepted: 30 November 2022

First Online: 12 December 2022

Declarations

:

: The studies involving human participants were reviewed and approved by the medical ethics committee of First Affiliated Hospital of Nanchang University. Due to the retrospective study design, the ethics committee of Ethics Committee of First Affiliated Hospital of Nanchang University approved a waiver of written informed consent.

: Not applicable.

: All authors declare that they have no conflict of interest to state.

Document is current

Any future updates will be listed below